Key Takeaways
- Revenue growth on track, margin reset: Q2 FY25 revenue grew strongly, putting the company on pace for ~30% top-line growth for FY25, but gross margin contracted sharply to 47% (from 57% in Q1) as the company traded price for market share and absorbed API losses.
- Market share grab is the priority, not near-term margins: Management is offering ~10% discounts to win new MCC customers from global leaders, betting that quality and service will lock them in and allow pricing power later.
- API is the margin drag and the margin promise: The acquired Trimax API unit is loss-making and pulling down profitability, but management expects a turnaround once 6-7 CEP approvals land by mid-FY26, unlocking 20% EBIT margins.
- Balance sheet levers are being pulled: A $10 crore FCCB umbrella approval, promoter warrants, and a pledge to be debt-free by year-end signal confidence, but the Trimax underperformance and delayed Middle East revenue raise execution risk.
- What to watch next quarter: Whether gross margin stabilizes as guided, progress on the first CEP approval (Propafenone, due March 2025), and any tangible revenue from the new pharmaceutical coatings or nutraceuticals segments.
Revenue Growth & Market Share Strategy
- MCC capacity driving volume: Utilization of the expanded 7,000 MTPA MCC capacity reached 75%, and management expects 50% of new capacities to be utilized by end of March 2025, with full absorption by end of next year.
- Pricing sacrificed for penetration: To win customers from the world's top two MCC players, Sigachi offers new customers a ~10% discount, planning to raise prices once the relationship is established on quality and service; existing customers are not given discounts.
- O&M segment steady: The asset-light O&M business grew 19.8% YoY in H1 FY25, anchored by partnerships with Gujarat Alkalis, Aditya Birla Group, ONGC, and Adani, though no new partners were added this quarter.
- New product adjacencies launched: Entry into pharmaceutical coatings with PureCoat and UltraMod brands leverages the existing MCC customer base; operations have commenced and sampling is underway.
Amit Raj Sinha: "Till the time they do not experience you, they do not value you. The moment they experience you, they value your products, they use your products, then they cannot let you go. This is what is bringing forward a value proposition with respect to your competition."
Margin Analysis: The Gross Margin Reset
- Gross margin fell 10pp QoQ to 47%: The contraction was driven by three factors: PLI income recognized in Q2 inflating the revenue base, pricing compromises to penetrate markets with enhanced capacity, and the loss-making API segment contribution.
- Employee costs rose with O&M mix: Employee benefit expenses moved from 14% to 18% of revenue because O&M revenue growth directly drives manpower costs; in the O&M segment, manpower is the primary expense.
- Freight costs a structural headwind: Other expenses rose on higher freight, and most exports are on CIF basis; freight cost increases are passed on mostly in the same quarter, though timing varies across 60+ countries and 300+ customers.
- Recovery promised from Q3: Management stated margins are expected to move upward from Q3 onwards with no further decline anticipated, and guided to full-year EBITDA margins of around 21%-22%.
Amit Raj Sinha: "I think in the short term, we will work to see that we are sustaining the margins. In the long term, we are working to see that we ramp it better because API's turnaround and improvement in the EBITDA is going to take time because the CEP approvals take at least 3 quarters."
API Segment: The Turnaround Bet
- Trimax is currently loss-making: The acquired API unit has not met projections due to delays in obtaining approvals, and management declined to provide segmented margins when asked.
- Transition from intermediates to APIs underway: The company is moving its product portfolio beyond intermediates toward CEP-approved APIs, with key products including Propafenone and Pregabalin; the facility is already USFDA approved for advanced intermediates.
- CEP approvals are the iron gate: The first CEP approval (Propafenone Hydrochloride) is expected by March 2025, effective Q1 FY26; management targets 6-7 CEP approvals by mid-FY26, which would unlock regulated market access and 20% EBIT margins.
- Capacity expansion timed with approvals: An additional 150 KL expansion commences January 2025 with full operations by January 2026; management expects 95%-100% utilization by mid-FY26, with estimated turnover of INR90-100 crores from the 100 KL capacity.
- API revenue mix target: Management corrected earlier higher guidance, now targeting APIs at nearly 30% of total revenue for the current financial year, and 20-25% of overall revenue in 2-3 years.
Amit Raj Sinha: "Once the CEP approval comes in, most chunk of our regulated customers would immediately go in for sampling and stability of the formulation. And once the stability is done, maybe meanwhile they would come for a customer comfort audit and subsequently start trials."
International Expansion & New Facilities
- US manufacturing facility planned: A proposed US plant aims to reduce transportation time (currently ~60 days) and freight costs; the FCCB fundraise is partly earmarked for this.
- Middle East expansion progressing slowly: Sigachi Arabia (75:25 JV with Saudi National Projects) and Sigachi Global (75:25 JV with iConnect) are operational but have let go of certain opportunities deemed unsustainable or too risky; management expects revenue from the next financial year.
- Dubai entities a near-term drag: Newly incorporated Dubai subsidiaries are initially not making profits, contributing to the gross margin decline.
- Dahej expansion continues: An additional 18-acre plot acquired in the same SEZ premises, with environmental clearance being obtained; the 1,800 MTPA CCS facility on site is scheduled for commercialization by FY26, with approval expected by December 2024 and 18 months to commission.
Amit Raj Sinha: "We are just trying to work out and have a fair mix of opportunities which remain sustainable and are risk balanced. So, on account of that, we have let go certain opportunities and we did not really look at them because we did not feel that we were in a position to be able to execute those orders, standards, products in line with those stipulated norms."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY25 revenue growth | Marginally better than 25-30%, probably touching 30% top-line growth | FY25 full year |
| FY25 EBITDA margin | Around 21%-22% | FY25 full year |
| Gross margin trajectory | Margins to move upward from Q3; no further decline expected | Q3 FY25 onwards |
| Debt-free status | Company will be debt free | End of FY25 |
| First CEP approval | Propafenone Hydrochloride CEP completion | By March 2025 |
| API capacity utilization | 95%-100% of capacity utilized | By mid-FY26 |
| CEP approvals count | At least 6-7 CEP approvals in place | By mid-FY26 |
| API EBIT margins | 20% EBIT margins on CEP-approved products | Once CEP approvals in place |
| CCS facility commercialization | 1,800 MTPA CCS facility in Dahej | By FY26 |
| API capacity expansion | Additional 150 KL expansion; full operations | Commencing Jan 2025; full ops by Jan 2026 |
| Nutraceuticals trial orders | Reasonable quantity of trial orders from nutraceuticals customers | By Jan or Feb 2025 |
| Sigachi Arabia revenue | Revenue from Middle East JV | Next financial year (FY26) |
| PLI income continuity | PLI incentives to continue | Till FY28 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Operating income | ₹124.9 cr, up 25.91% YoY |
| EBITDA | ₹29 cr, up 36.91% YoY |
| EBITDA margin | 21.38% |
| Gross margin | 47%, compared to 57% in Q1 FY25 and 53% in Q2 FY24 |
| Revenue growth guidance (FY25) | ~30% top-line growth |
| Revenue growth guidance (annual) | Not less than 25% to 30% every year |
| EBITDA margin guidance | 21%–22% |
| MCC capacity utilization | 50% (8,153 units), up 20% vs corresponding previous year |
| MCC realization | ₹212 per kg |
| O&M revenue growth (H1 FY25) | ~19.8% YoY |
| API revenue share (H1 FY25) | 8% of overall revenue, up from 4% in H1 FY24 |
| API revenue target | 20%–25% of overall revenue in next 2–3 years |
| API capacity utilization target | 95%–100% by mid-FY26 |
| Employee benefit expenses | ~18% of top line, up from ~14% last year |
| Promoter shareholding (post preferential issue) | 46%–48% |